Karl-Franzens Biotech Spin-Out, ProtAffin Biotechnologie AG Gets €2.65M for Kidney Transplant Drug

The Company will use the funds to progress its lead product PA04-001 through pre-clinical development and to further validate its unique CellJammer™ discovery technology. ProtAffin is using its CellJammer™ technology developed by the company's CSO Andreas Kungl, to modify chemokines towards increased glycosaminoglycan (GAGs) affinity and removal of their GPCR activation domains. These novel protein drugs act as anti-inflammatory agents, by blocking the trafficking of leukocytes to sites of acute and chronic inflammation. The Company’s lead product PA04-001 has been derived from IL-8, and its anti-neutrophil infiltration activity has been extensively characterised in vitro. PA04-001 has also shown potent efficacy in a number of in vivo models of inflammatory diseases. The Company plans to develop PA04-001 for ischemia/reperfusion injury in the setting of kidney transplantation.

Back to news